Search tips
Search criteria 


Logo of jnnpsycJournal of Neurology, Neurosurgery and PsychiatryVisit this articleSubmit a manuscriptReceive email alertsContact usBMJ
J Neurol Neurosurg Psychiatry. 1993 August; 56(8): 925–928.
PMCID: PMC1015155

Vigabatrin and depression.


Ten patients who developed a major depressive episode in association with vigabatrin treatment for intractable epilepsy are reported. The depression usually occurred early in the course of treatment, but when delayed followed a recent increase in dose. Depressive symptoms occurred at doses varying between 1.5 g and 4 g a day, often but not always when patients were experiencing a decrease in their seizure frequency. Most patients had a history of affective disturbance, sometimes in association with other GABAergic drugs. The observations support a possible role for GABAergic mechanisms in the biology of mood disorders.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (683K), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Ring HA, Heller AJ, Farr IN, Reynolds EH. Vigabatrin: rational treatment for chronic epilepsy. J Neurol Neurosurg Psychiatry. 1990 Dec;53(12):1051–1055. [PMC free article] [PubMed]
  • Perry TL, Kish SJ, Hansen S. gamma-Vinyl GABA: effects of chronic administration on the metabolism of GABA and other amino compounds in rat brain. J Neurochem. 1979 Jun;32(6):1641–1645. [PubMed]
  • Schechter PJ, Hanke NF, Grove J, Huebert N, Sjoerdsma A. Biochemical and clinical effects of gamma-vinyl GABA in patients with epilepsy. Neurology. 1984 Feb;34(2):182–186. [PubMed]
  • Lloyd KG, Morselli PL, Bartholini G. GABA and affective disorders. Med Biol. 1987;65(2-3):159–165. [PubMed]
  • Petty F, Schlesser MA. Plasma GABA in affective illness. A preliminary investigation. J Affect Disord. 1981 Dec;3(4):339–343. [PubMed]
  • Petty F, Sherman AD. Plasma GABA levels in psychiatric illness. J Affect Disord. 1984 Apr;6(2):131–138. [PubMed]
  • Gerner RH, Hare TA. CSF GABA in normal subjects and patients with depression, schizophrenia, mania, and anorexia nervosa. Am J Psychiatry. 1981 Aug;138(8):1098–1101. [PubMed]
  • Gold BI, Bowers MB, Jr, Roth RH, Sweeney DW. GABA levels in CSF of patients with psychiatric disorders. Am J Psychiatry. 1980 Mar;137(3):362–364. [PubMed]
  • Kasa K, Otsuki S, Yamamoto M, Sato M, Kuroda H, Ogawa N. Cerebrospinal fluid gamma-aminobutyric acid and homovanillic acid in depressive disorders. Biol Psychiatry. 1982 Aug;17(8):877–883. [PubMed]
  • Rabe LS, Buck SH, Moreno L, Burks TF, Dafny N. Neurophysiological and thermoregulatory effects of capsaicin. Brain Res Bull. 1980 Nov-Dec;5(6):755–758. [PubMed]
  • Lydiard RB, Laraia MT, Ballenger JC, Howell EF. Emergence of depressive symptoms in patients receiving alprazolam for panic disorder. Am J Psychiatry. 1987 May;144(5):664–665. [PubMed]
  • Nurnberger JI, Jr, Berrettini WH, Simmons-Alling S, Guroff JJ, Gershon ES. Intravenous GABA administration is anxiogenic in man. Psychiatry Res. 1986 Oct;19(2):113–117. [PubMed]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Group